Triamcinolone acetonide hydrofluoroalkane inhalation - Abbott Laboratories

Drug Profile

Triamcinolone acetonide hydrofluoroalkane inhalation - Abbott Laboratories

Alternative Names: Azmacort HFA; Azmacort HFA-134a; KI 03216; RG 5016; Triamcinolone acetonide HFA inhalation - Abbott Laboratories; Triamcinolone acetonide HFA inhalation - Kos

Latest Information Update: 22 Jan 2013

Price : $50

At a glance

  • Originator Aventis
  • Developer Abbott Laboratories
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company known as AbbVie
  • 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top